Silo Pharma (SILO) Operating Expenses (2010 - 2026)
Silo Pharma (SILO) posted Operating Expenses of $1.6 million for Q1 2026, up 103.1% sequentially from $783861.0 in Q4 2025, and up 43.33% YoY from $1.1 million in Q1 2025.
Silo Pharma (SILO) Operating Expenses (2010 - 2026) Analysis & Trends
Silo Pharma has reported Operating Expenses for 14 years, with the latest figure at $1.6 million in Q1 2026.
- Quarterly Operating Expenses rose 43.33% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (down 3.95% YoY) and the FY2025 annual result came in at $4.3 million, down 9.71% from the prior year.
- Operating Expenses grew to $1.6 million in Q1 2026 per SILO's latest filing, from $783861.0 in the prior quarter.
- Over five years, Operating Expenses peaked at $1.8 million in Q4 2024 and troughed at $510851.0 in Q2 2022.
- A 5-year average of $1.1 million and a median of $1.0 million in 2024 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses surged 121.5% in 2023, then slumped 57.16% in 2025.
- Over 5 years, Operating Expenses stood at $1.7 million in 2022, then slipped by 29.47% to $1.2 million in 2023, then soared by 55.04% to $1.8 million in 2024, then plunged by 57.16% to $783861.0 in 2025, then soared by 103.1% to $1.6 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $1.6 million, $783861.0, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Silo Pharma | 3.04 Mn | 3.04 Mn | - | 928,949.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 928,949.00 |
| Mar 31, 2026 | 1.59 Mn |
| Dec 31, 2025 | 783,861.00 |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.27 Mn |
| Mar 31, 2025 | 1.11 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.02 Mn |
| Mar 31, 2024 | 896,079.00 |
| Dec 31, 2023 | 1.18 Mn |
| Sep 30, 2023 | 789,964.00 |
| Jun 30, 2023 | 1.13 Mn |
| Mar 31, 2023 | 820,051.00 |
| Dec 31, 2022 | 1.67 Mn |
| Sep 30, 2022 | 965,720.00 |
| Jun 30, 2022 | 510,851.00 |
| Mar 31, 2022 | 543,825.00 |
| Dec 31, 2021 | 958,982.00 |
| Sep 30, 2021 | 480,508.00 |